ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GLR2053 Tablets

A development code.

Its studies are mostly in Dermatitis, Atopic, led by Gan & Lee Pharmaceuticals.

Furthest: phase 1, since Oct 27, 20261 company-led study, 1 open or runningNext primary completion: Jul 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gan & Lee Pharmaceuticals11 open or runningphase 1since Oct 27, 2026Oct 27, 2026Jul 30, 2027phase 1 · NCT07920783

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2026First study: phase 1 study in Dermatitis, AtopicFirst studyNCT07920783 · 124 planned · China

Ahead

  1. Jul 30, 2027Primary completion: phase 1 study in Dermatitis, AtopicNCT07920783

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07920783Dermatitis, Atopic · China1Not yet recruitingJul 30, 2027124

How it is read

Names in the registry

  • “GLR2053 Tablets”, 1 entry

Codes read as this program: GLR2053.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.